Join us live where we discuss how CRISPR screening is proving to be a robust platform for the identification and validation of new biological targets for disease treatment. It is hoped that CRISPR screens will accelerate drug development by providing more robust targets for validation than siRNA screens, for example.
By Dr H Michael Shepard (Enosi Life Sciences)
By Ramya Sriram (Kolabtree)
By Baidyanath Dash (G3 Systems)
By Dr Isaac Karimi (Razi University)
By Anthony Finbow (Eagle Genomics)
By Hannah Balfour (Drug Target Review)